Moreover, identifying the cancer types and patient subgroups that would benefit most from CX3CR1-engineered CAR-T cells, developing reliable biomarkers, and optimizing combination strategies with IL-15 or immune checkpoint inhibitors remain key areas for future investigation. This evidence concerns the gene IL15 and cancer.